According to 10x Genomics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -25.1879. At the end of 2022 the company had a P/E ratio of -24.8.
Year | P/E ratio | Change |
---|---|---|
2022 | -24.8 | -91.35% |
2021 | -286 | 941.86% |
2020 | -27.5 | -79.77% |
2019 | -136 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Organovo ONVO | -0.5000 | -98.01% | ๐บ๐ธ USA |
Orchard Therapeutics
ORTX | -2.69 | -89.31% | ๐ฌ๐ง UK |
Novavax NVAX | -0.6648 | -97.36% | ๐บ๐ธ USA |
Novocure
NVCR | -8.40 | -66.64% | Jersey |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.